Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications

    ... leukemia (AML). Although the hypomethylating agent azacitidine prolongs survival among patients with higher risk (HR)-MDS ...

    Research Article last updated 02/21/2017 - 9:34am.

  2. Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations.

    ... June 4, 2013 Azacitidine is recommended for patients with higher-risk ... to other therapies. However, standard treatment with azacitidine has not been optimized and many issues about the use of azacitidine ...

    Research Article last updated 07/09/2013 - 3:03pm.

  3. Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes

    ... aimed to directly compare the efficacy and safety of azacitidine and decitabine in patients with myelodysplastic ... to leukaemic transformation, and adverse outcomes between azacitidine and decitabine. To minimize the effects of treatment selection bias ...

    Research Article last updated 03/05/2013 - 9:07am.

  4. Patients with Myelodysplastic Syndromes Treated with Azacitidine in Clinical Practice: The AVIDA® Registry

    ... ABSTRACT The AVIDA registry evaluated azacitidine usage and effectiveness in unselected MDS patients in ... with previous reports. The AVIDA registry data support azacitidine effectiveness and safety in lower- or higher-risk MDS patients ...

    Research Article last updated 07/07/2014 - 9:42am.

  5. Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS

    ... clinical or molecular predictors of benefit from azacitidine therapy in patients with myelodysplastic syndromes ... of platelet count at start of second cycle of azacitidine therapy compared to baseline was associated with achieving ... between platelet count doubling after first cycle of azacitidine therapy and probability of achieving objective response. Among ...

    Research Article last updated 08/04/2014 - 8:37am.

  6. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia

    ... We investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined ... bone marrow blasts . Patients were treated with azacitidine, with one of three dosage regimens: for 5 days (AZA 5); 7 days ...

    Research Article last updated 05/22/2014 - 9:28am.

  7. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

    ... The cytidine nucleoside analogue and epigenetic modifier azacitidine is approved in the U.S. for the treatment of all ... to the World Health Organization classification. Benefits of azacitidine treatment of patients with AML with >30% blasts have also been ...

    Research Article last updated 12/09/2015 - 8:49am.

  8. Genetics and Epigenetics of Myelodysplastic Syndromes and Response to Drug Therapy: New Insights

    ... in TET2 molecule show better response to treatment with azacitidine . IDH and DNMT3A mutations are associated with a good response ...

    Research Article last updated 02/01/2017 - 8:15am.

  9. Expression of nucleoside metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine

    ... The nucleoside analog azacitidine (AZA) is used in the treatment of myelodysplastic syndromes ...

    Research Article last updated 11/14/2013 - 11:22am.

  10. Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS

    ... the combination of vadastuximab talirine (SGN-CD33A) and azacitidine in subjects with previously untreated International ... of vadastuximab talirine (SGN-CD33A) in combination with azacitidine (in the open-label Phase 1 portion), and to compare the overall ...

    Clinical Trial last updated 06/19/2017 - 2:44pm.